Abstract

The coupling of cannabinoid receptors, CB1 and CB2, to G protein-coupled inward rectifier potassium channels, GIRK1 and GIRK2, modulates neuronal excitability in the human brain. The present study established and validated the functional expression in a Xenopus laevis oocyte expression system of CB1 and CB2 receptors, interacting with heteromeric GIRK1/2 channels and a regulator of G protein signaling, RGS4. This ex vivo system enables the discovery of a wide range of ligands interacting orthosterically or allosterically with CB1 and/or CB2 receptors. WIN55,212-2, a non-selective agonist of CB1 and CB2, was used to explore the CB1- or CB2-GIRK1/2-RGS4 signaling cascade. We show that WIN55,212-2 activates CB1 and CB2 at low concentrations whereas at higher concentrations it exerts a direct block of GIRK1/2. This illustrates a dual modulatory function, a feature not described before, which helps to explain the adverse effects induced by WIN55,212-2 in vivo. When comparing the effects with other typical cannabinoids such as Δ9-THC, CBD, CP55,940, and rimonabant, only WIN55,212-2 can significantly block GIRK1/2. Interestingly, the inward rectifier potassium channel, IRK1, a non-G protein-coupled potassium channel important for setting the resting membrane voltage and highly similar to GIRK1 and GIRK2, is not sensitive to WIN55,212-2, Δ9-THC, CBD, CP55,940, or rimonabant. From this, it is concluded that WIN55,212-2 selectively blocks GIRK1/2.

Highlights

  • Oocytes co-injected with cannabinoid receptor type 1 (CB1) or CB2, GIRK1/2, and RGS4 cRNAs were voltageclamped at −90 mV

  • WIN55,212-2 under high concentrations significantly blocked GIRK1/2 activated by CB1 or CB2, and inhibited the Cannabinoid receptors (CB)-GIRK1/2 signaling

  • WIN55,212-2 is an agonist of CB1 and CB2 and can activate CB-G protein-coupled inward rectifier K+ (GIRK) signaling in the CB-GIRK1/2-RGS4 coupling, it can block GIRK1/2 activated by CB1 and CB2 under high concentrations

Read more

Summary

Introduction

Cannabinoid receptors (CB) are G protein-coupled receptors (GPCRs) that have attracted broad attention since they are regarded as promising therapeutic targets for multiple pathologies, such as pain, epilepsy, anorexia, Parkinson’s disease, and Alzheimer’s disease [1]. Cannabinoid receptors are primarily classified as CB1 and CB2. CB1 is one of the most abundant GPCRs in the human brain [2], while CB2 was originally considered to be confined in the peripheral organs of humans [3,4]. Ligands of CB1 and/or CB2 ( commonly known as cannabinoids), through their binding to cannabinoid receptors in the brain, produce a wide variety of effects. Activating CB1 generates psychotropic effects including euphoria, enhancement of sensory perception, antinociception, appetite stimulation, and impairment of memory [1]. Activating CB2 produces antinociception, antiinflammation, and neuroprotection [1]. In the brain, signaling pathways of activating

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call